+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Outsourcing Market - Global Forecast to 2030- Product Image
Biologics Outsourcing Market - Global Forecast to 2030- Product Image
Sale

Biologics Outsourcing Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011402
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Outsourcing Market grew from USD 22.87 billion in 2024 to USD 25.81 billion in 2025. It is expected to continue growing at a CAGR of 12.36%, reaching USD 46.04 billion by 2030.

As biopharmaceutical pipelines continue to expand, the outsourcing of biologics manufacturing and development services has emerged as a strategic imperative for leading life sciences organizations. Contract development and manufacturing organizations (CDMOs) now serve as vital partners, offering specialized expertise in cell line development, process optimization, analytics and scale-up that most internal teams cannot match at equivalent speed or cost. By leveraging external capacity for tasks ranging from early research to commercial fill/finish, sponsors accelerate time to market and reduce capital expenditure burdens. Moreover, this collaborative model enables organizations to focus their internal resources on core competencies such as target discovery and clinical strategy. With regulatory authorities increasingly supportive of outsourced data packages and single-use technologies driving agile production, the biologics outsourcing market is transitioning from a cost-arbitrage play to a value-creation engine. This shift underscores the importance of understanding evolving technological, regulatory and geopolitical forces to navigate an environment where agility, quality and compliance define competitive advantage.

Transformative Shifts Reshaping the Biologics Outsourcing Landscape

Building on the momentum of rapid pipeline expansion, the biologics outsourcing sector is undergoing transformative shifts that will redefine industry norms. First, digital integration has moved from pilot projects to full-scale deployment: real-time analytics, digital twins of manufacturing processes and predictive quality models now drive decision-making at every stage. Second, regulatory harmonization across major markets has reduced approval complexity, enabling CDMOs to standardize quality management systems and submit unified data dossiers. Third, sustainability imperatives have prompted a move toward single-use and closed-loop systems, minimizing water consumption and facility footprints while accelerating changeover. Fourth, personalized medicine trends are reshaping capacity allocation, as CDMOs introduce modular facilities for low-volume, high-value therapeutics alongside large-scale monoclonal antibody plants. Fifth, supply chain resilience has emerged as a priority: through nearshoring strategies and strategic stockpiling, organizations mitigate geopolitical risks and minimize disruption. In parallel, strategic alliances between biotech innovators and established CDMOs are proliferating, combining cutting-edge discovery platforms with robust manufacturing networks. Collectively, these shifts are forging a new ecosystem in which speed, flexibility and sustainability are paramount.

Cumulative Impact of 2025 United States Tariffs on Biologics Outsourcing

The implementation of a new tranche of United States tariffs in 2025 has introduced a complex layer of cost pressures and strategic realignments across the biologics outsourcing value chain. As import duties on key raw materials and components rose, manufacturing overheads at facilities relying on international supply streams increased by double-digit percentages, compelling sponsors to revisit sourcing strategies. Many organizations responded by shifting procurement toward domestic suppliers or near-shored CDMOs, thereby trading off unit cost advantages for greater predictability and lower lead times. At the same time, CDMOs with global footprints have renegotiated supplier contracts and restructured their logistics networks to circumvent the most punitive tariff brackets. This environment has also driven heightened interest in vertical integration, as some players acquire control over reagent production or analytical testing labs to insulate margins from external duties. Moreover, the uncertainty around potential further tariff adjustments has led to more robust scenario planning, with sponsors and service providers incorporating duty-related contingencies into project timelines. In aggregate, the 2025 tariff landscape is shifting the outsourcing equation, privileging partners with flexible networks and cost-avoidance expertise.

Key Insights from Biologics Outsourcing Market Segmentation

When analyzing product type, monoclonal antibodies dominate the outsourcing landscape; chimeric constructs remain prominent alongside human molecules, the latter presenting as either fragmented or full-length formats, while humanized antibodies predominantly consist of the IgG subclass with emerging demand for IgM formats. Turning to source, mammalian cells such as CHOK1 and NS0 underpin high-titer production, microbial hosts including bacterial systems and yeast platforms like Pichia pastoris and Saccharomyces cerevisiae offer cost-effective alternatives, and niche plant-based factories leverage moss bioreactors for specialized applications. Regarding application, autoimmune disorders led by psoriasis and rheumatoid arthritis represent a mature opportunity, infectious diseases span bacterial pneumonia and tuberculosis as well as viral indications, and oncology pipelines target breast cancer, colorectal cancer and lung cancer. Among end users, biotechnology companies maintain robust internal pipelines while contract research organizations provide specialized clinical trial management and regulatory support services to pharmaceutical companies and research laboratories. This multi-tiered segmentation underscores the necessity of tailored workflows and strategic investments that address distinct technical and regulatory requirements across each segment.

Regional Dynamics Driving Biologics Outsourcing Growth

Across the Americas, the ecosystem benefits from deep R&D expertise, abundant venture activity and regulatory agencies that support expedited pathways for breakthrough biologics, fostering high-value outsourcing engagements focused on innovation and complex modalities. In Europe, the Middle East and Africa, a mosaic of regulatory frameworks and mature manufacturing hubs enables service providers to offer region-specific quality compliance and to support market entry strategies tailored to diverse patient safety requirements. Meanwhile, Asia-Pacific has emerged as a cost-effective powerhouse, with nations such as China, South Korea and India rapidly expanding biomanufacturing infrastructure, cultivating skilled workforces and incentivizing foreign investment in biologics capacity. This regional diversification drives sponsors to adopt hybrid outsourcing models that leverage the high-value innovation clusters of the Americas, the regulatory sophistication of EMEA and the scalable production advantages of Asia-Pacific. Consequently, agility in contract negotiation and supply-chain design becomes critical for organizations aiming to optimize cost, compliance and time to market across global operations.

Strategic Roles of Leading Biologics Outsourcing Companies

Global leaders such as AbbVie Inc. and Amgen Inc. demonstrate full integration of CMC and clinical scale-up, while Biocon Limited and Samsung Biologics Co., Ltd. aggressively expand capacity in Asia-Pacific hubs. Boehringer Ingelheim GmbH and Merck KGaA emphasize biologics innovation through proprietary expression platforms, whereas Catalent, Inc. and Thermo Fisher Scientific Inc. invest heavily in single-use technologies and downstream processing automation. Charles River Laboratories International, Inc. and Covance Inc. differentiate through comprehensive preclinical testing and safety assessment, and Icon plc alongside Parexel International Corporation reinforce clinical trial management and regulatory support services. Lonza Group AG and Fujifilm Diosynth Biotechnologies spearhead global manufacturing networks that accommodate both clinical- and commercial-scale volumes, while Genentech, Inc. and Novartis AG leverage in-house discovery platforms to streamline handoffs to external production partners. Pfizer Inc. and Eli Lilly and Company integrate end-to-end supply-chain management, maximizing visibility and risk mitigation. Finally, Sandoz International GmbH and WuXi AppTec Co., Ltd. focus on biosimilar development and contract R&D, rounding out a highly competitive ecosystem oriented toward specialized capabilities and geographic reach.

Actionable Recommendations for Industry Leaders in Biologics Outsourcing

To thrive in this dynamic environment, industry leaders must adopt a proactive, multifaceted strategy that addresses regulatory complexity, technological advancement and supply-chain resilience. First, organizations should implement integrated digital platforms that unify development data, manufacturing analytics and quality control metrics, thereby reducing cycle times and enabling predictive risk management. Second, sponsors and CDMOs need to diversify raw-material sources and incorporate tariff- and trade-compliance modules into procurement workflows to preempt cost volatility. Third, accelerating cell line engineering initiatives-leveraging CRISPR-based editing and high-throughput screening-will enhance yield and reduce downstream processing burdens. Fourth, forging strategic partnerships across regions-combining the innovation clusters of North America with the scale advantages of Asia-Pacific and the regulatory acumen of EMEA-will optimize global supply networks. Fifth, investing in green manufacturing practices, such as water-recycling systems and energy-efficient bioreactors, will satisfy ESG mandates while reducing operational expenditure. Finally, engaging in early and continuous dialogue with regulatory authorities across target markets ensures alignment on data packages and compliance expectations, minimizing approval risks and expediting market entry.

Conclusion: Navigating the Future of Biologics Outsourcing

The biologics outsourcing landscape stands at a pivotal inflection point characterized by rapid technological evolution, shifting trade dynamics and increasingly stringent environmental expectations. Organizations that embrace digitalization, forge agile partnerships and prioritize sustainable manufacturing will secure distinct competitive advantages. By integrating predictive analytics into process development, expanding global production footprints and aligning early with regulatory bodies, industry players can mitigate risk and accelerate time to market. Moreover, focusing on modular facility designs and flexible supply-chain architectures will enable rapid adaptation to emerging therapeutic modalities and geopolitical disruptions. In this context, collaboration between sponsors and service providers transforms transactional engagements into strategic alliances that foster innovation and drive commercial success. Ultimately, the capacity to anticipate market shifts and operationalize best-in-class practices will determine which organizations lead the next generation of biologics development.

Market Segmentation & Coverage

This research report categorizes the Biologics Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Monoclonal Antibodies
    • Chimeric
    • Human
      • Fragmented
      • Full-Length
    • Humanized
      • IgG
      • IgM
  • Mammalian Cells
    • CHOK1
    • NS0
  • Microbial
    • Bacteria
    • Yeast
      • Pichia Pastoris
      • Saccharomyces Cerevisiae
  • Plant-Based
    • Moss
  • Autoimmune Disorders
    • Psoriasis
    • Rheumatoid Arthritis
  • Infectious Diseases
    • Bacterial
      • Pneumonia
      • Tuberculosis
    • Viral
  • Oncology
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
  • Biotechnology Companies
  • Contract Research Organizations
    • Clinical Trial Management
    • Regulatory Support
  • Pharmaceutical Companies
  • Research Laboratories

This research report categorizes the Biologics Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biologics Outsourcing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Covance Inc.
  • Eli Lilly and Company
  • Fujifilm Diosynth Biotechnologies
  • Genentech, Inc.
  • Icon plc
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Parexel International Corporation
  • Pfizer Inc.
  • Samsung Biologics Co., Ltd.
  • Sandoz International GmbH
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics Outsourcing Market, by Product Type
8.1. Introduction
8.2. Monoclonal Antibodies
8.2.1. Chimeric
8.2.2. Human
8.2.2.1. Fragmented
8.2.2.2. Full-Length
8.2.3. Humanized
8.2.3.1. IgG
8.2.3.2. IgM
9. Biologics Outsourcing Market, by Source
9.1. Introduction
9.2. Mammalian Cells
9.2.1. CHOK1
9.2.2. NS0
9.3. Microbial
9.3.1. Bacteria
9.3.2. Yeast
9.3.2.1. Pichia Pastoris
9.3.2.2. Saccharomyces Cerevisiae
9.4. Plant-Based
9.4.1. Moss
10. Biologics Outsourcing Market, by Application
10.1. Introduction
10.2. Autoimmune Disorders
10.2.1. Psoriasis
10.2.2. Rheumatoid Arthritis
10.3. Infectious Diseases
10.3.1. Bacterial
10.3.1.1. Pneumonia
10.3.1.2. Tuberculosis
10.3.2. Viral
10.4. Oncology
10.4.1. Breast Cancer
10.4.2. Colorectal Cancer
10.4.3. Lung Cancer
11. Biologics Outsourcing Market, by End-Use
11.1. Introduction
11.2. Biotechnology Companies
11.3. Contract Research Organizations
11.3.1. Clinical Trial Management
11.3.2. Regulatory Support
11.4. Pharmaceutical Companies
11.5. Research Laboratories
12. Americas Biologics Outsourcing Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Biologics Outsourcing Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Biologics Outsourcing Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Amgen Inc.
15.3.3. Biocon Limited
15.3.4. Boehringer Ingelheim GmbH
15.3.5. Catalent, Inc.
15.3.6. Charles River Laboratories International, Inc.
15.3.7. Covance Inc.
15.3.8. Eli Lilly and Company
15.3.9. Fujifilm Diosynth Biotechnologies
15.3.10. Genentech, Inc.
15.3.11. Icon plc
15.3.12. Lonza Group AG
15.3.13. Merck KGaA
15.3.14. Novartis AG
15.3.15. Parexel International Corporation
15.3.16. Pfizer Inc.
15.3.17. Samsung Biologics Co., Ltd.
15.3.18. Sandoz International GmbH
15.3.19. Thermo Fisher Scientific Inc.
15.3.20. WuXi AppTec Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOLOGICS OUTSOURCING MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS OUTSOURCING MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS OUTSOURCING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOLOGICS OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOLOGICS OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS OUTSOURCING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FRAGMENTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FULL-LENGTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IGG, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IGM, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CHOK1, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NS0, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PICHIA PASTORIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MOSS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGULATORY SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 107. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 109. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 110. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 111. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 112. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 113. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 114. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 115. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 116. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 118. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 119. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 120. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 121. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 122. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 189. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 191. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 192. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 193. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 194. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 195. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 196. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 197. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 198. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 200. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 201. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 202. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 203. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 204. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 205. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 207. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 208. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 209. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 210. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 211. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 212. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 213. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 214. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 216. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 217. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 218. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 219. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 220. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 237. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 239. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 240. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 241. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 242. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 243. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 244. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 245. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 246. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 248. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 249. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 250. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 251. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 275. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 276. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 277. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 278. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 281. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 285. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 287. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 288. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 289. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 290. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 291. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 293. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 294. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 295. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 296. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 297. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 317. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT-BASED, 2018-2030 (USD MILLION)
TABLE 326. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 327. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 328. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 329. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 330. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 331. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 332. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 333. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 334. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 335. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
TABLE 336. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY HUMANIZED, 2018-2030 (USD MILLION)
TABLE 337. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 338. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
TABLE 339. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY MICROBIAL, 2018-2030

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Covance Inc.
  • Eli Lilly and Company
  • Fujifilm Diosynth Biotechnologies
  • Genentech, Inc.
  • Icon plc
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Parexel International Corporation
  • Pfizer Inc.
  • Samsung Biologics Co., Ltd.
  • Sandoz International GmbH
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service, By Phase, By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Biologics Regulatory Affairs Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Biologics Regulatory Affairs Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions - Product Image

Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions

  • Report
  • 799 Pages
  • Global
From
Biologics Outsourcing Market Report 2025 - Product Image

Biologics Outsourcing Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Biologics Outsourcing Market

The biologics outsourcing market is a subset of the pharmaceutical manufacturing industry, focusing on the production of biologics. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and vaccines. These molecules are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. As biologics become increasingly important in the treatment of these diseases, the demand for biologics outsourcing has grown. Biologics outsourcing involves the transfer of biologics production from the pharmaceutical company to a third-party manufacturer. This allows the pharmaceutical company to focus on the development and marketing of their products, while the third-party manufacturer handles the production. This arrangement also allows the pharmaceutical company to access the latest technologies and expertise in biologics production. Companies in the biologics outsourcing market include Lonza, Boehringer Ingelheim, Merck KGaA, and Fujifilm Diosynth Biotechnologies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.